

# Shunichi Sugawara

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4036754/publications.pdf>

Version: 2024-02-01

31  
papers

11,390  
citations

430874

18  
h-index

454955

30  
g-index

33  
all docs

33  
docs citations

33  
times ranked

11447  
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIa Non-small-Cell Lung Cancer With EGFR Mutation (IMPACT). <i>Journal of Clinical Oncology</i> , 2022, 40, 231-241.	1.6	61
2	Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE. <i>Journal of Clinical Oncology</i> , 2022, 40, 180-188.	1.6	21
3	Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations. <i>European Journal of Cancer</i> , 2022, 162, 99-106.	2.8	30
4	A Randomized Phase II Study Comparing Nivolumab with Carboplatin+Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). <i>Clinical Cancer Research</i> , 2022, 28, 893-902.	7.0	35
5	Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE). <i>Oncology and Therapy</i> , 2022, 10, 253-262.	2.6	9
6	Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100317.	1.1	1
7	Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2022, 27, e410-e419.	3.7	9
8	Randomized phase II trial of carboplatin+nab-paclitaxel versus cisplatin+gemcitabine for chemotherapy-naïve squamous cell carcinoma: North Japan lung cancer study group 1302. <i>International Journal of Clinical Oncology</i> , 2021, 26, 515-522.	2.2	3
9	Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial. <i>European Journal of Cancer</i> , 2021, 149, 14-22.	2.8	30
10	Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2021, 10, 4796-4804.	2.8	13
11	First-line pembrolizumab vs chemotherapy in metastatic non-small cell lung cancer: KEYNOTE-024 Japan subset*. <i>Cancer Science</i> , 2021, 112, 5000-5010.	3.9	6
12	Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers. <i>PLoS ONE</i> , 2021, 16, e0260500.	2.5	2
13	Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ09 Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 115-123.	1.6	327
14	Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCCG1601). <i>Oncologist</i> , 2020, 25, e1451-e1456.	3.7	5
15	Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, e196828.	7.1	48
16	Association Between Skin Reaction and Clinical Benefit in Patients Treated with Anti-Programmed Cell Death 1 Monotherapy for Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, e536-e544.	3.7	39
17	Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. <i>Cancer</i> , 2019, 125, 4076-4083.	4.1	11
18	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 1819-1830.	13.7	2,347

#	ARTICLE	IF	CITATIONS
19	Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 376.	7.1	235
20	Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 29-36.	1.3	101
21	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan. <i>Lung Cancer</i> , 2019, 129, 55-62.	2.0	29
22	Relationship between Programmed Cell Death Protein Ligand 1 Expression and Immune-related Adverse Events in Non-small-cell Lung Cancer Patients Treated with Pembrolizumab. <i>JMA Journal</i> , 2019, 3, 58-66.	0.8	13
23	A Case of Pseudoprogression in Lung Adenocarcinoma Treated with Nivolumab. <i>Japanese Journal of Lung Cancer</i> , 2019, 59, 60-65.	0.1	0
24	Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2040-2051.	27.0	2,676
25	Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. <i>Oncologist</i> , 2018, 23, 1358-1365.	3.7	196
26	Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCC) 0901. <i>Lung Cancer</i> , 2017, 111, 38-42.	2.0	8
27	A phase II study of bevacizumab with carboplatin-pemetrexed in non-squamous non-small cell lung carcinoma patients with malignant pleural effusions: North East Japan Study Group Trial NEJ013A. <i>Lung Cancer</i> , 2016, 99, 131-136.	2.0	44
28	Weekly irinotecan combined with carboplatin for patients with small-cell lung cancer: A phase I study. <i>Respiratory Investigation</i> , 2015, 53, 156-160.	1.8	2
29	Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1805-1809.	1.1	32
30	Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802. <i>Respiratory Investigation</i> , 2014, 52, 190-194.	1.8	3
31	Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. <i>New England Journal of Medicine</i> , 2010, 362, 2380-2388.	27.0	5,032